Actively Recruiting
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
Led by Ruijin Hospital · Updated on 2024-09-19
104
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by PD-1/PD-L1 maintenance therapy
CONDITIONS
Official Title
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 years and 80 years at time of study entry
- ECOG performance status of 0 or 1
- Body weight greater than 30 kg
- Adequate bone marrow, liver, and kidney function
- Life expectancy of at least 3 months
- At least one measurable thoracic lesion suitable for 45 Gy/15 fractions radiotherapy
- Histologic or cytologic confirmation of small cell lung cancer
- Stage III-IV disease (TNM version 8)
- Adequate pulmonary function with FEV1 >1 L or >30% of predicted value and DLCO >30% of predicted value
- Patients with brain metastases eligible if asymptomatic or stable on treatment prior to study start
You will not qualify if you...
- Previous chemotherapy, immunotherapy, or radiotherapy for small-cell lung cancer
- Major surgery within the last 28 days
- History of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis, or HIV
- Uncontrolled intercurrent illness
- Other active malignancy
- Leptomeningeal carcinomatosis
- Use of immunosuppressive medication
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai jiaotong univestigy school of medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here